Serum Th1 and Th2 cytokine balance in patients of superficial transitional cell carcinoma of bladder pre- and post-intravesical combination immunotherapy

References

• Pyrah LN, Raper FP, Thomas GM. Report of a follow-up of papillary tumours of the bladder. Br J Urol 1964;36:4–25.
   Google Scholar
• Torti, FM, Lum, BL, Superficial carcinoma of the bladder: natural history and the role of interferons. Semin Oncol 1986;13:57–60.
   PubMedGoogle Scholar
• Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N Engl J Med 1991;325:1205–9.
   PubMed Web of Science ®Google Scholar
• Bohle A, Brandau S. Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol 2003;170:964–9.
   PubMed Web of Science ®Google Scholar
• Ratliff TL. Role of the immune response in BCG for bladder cancer. Eur Urol 1992;2:17–21.
   Google Scholar
• O’Donnell MA, DeWolf WC. Bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. New prospects for an old warhorse. Surg Oncol Clin N Am 1995;4:189–202.
   PubMedGoogle Scholar
• Luo Y, Chen X, Han R, O’Donnell MA. Recombinant bacille Calmette-Guerin BCG expressing human interferon-alpha 2B demonstrates enhanced immunogenicity. Clin Exp Immunol 2001;123:179–80.
   PubMedGoogle Scholar
• Belldegrun AS, Franklin JR, O’Donnell MA, Gomella LG, Klein E, Neri R, et al. Superficial bladder cancer: the role of interferon-alpha. J Urol 1998;159:1793–801.
   PubMed Web of Science ®Google Scholar
• Pryor K, Stricker P, Russell PI, Golovsky D, Penny R. Antiproliferative effects of bacillus Calmette-Guerin and interferon alpha 2b on human bladder cancer cells in vitro. Cancer Immunol Immunother 1995;41:309–16.
   PubMedGoogle Scholar
• Bercovich E, Deriu M, Manferrari F, Irianni G. BCG vs. BCG plus recombinant alpha-interferon 2b in superficial tumors of the bladder. Arch Ital Urol Androl 1995;67:257–60.
   PubMedGoogle Scholar
• Stricker P, Pryor K, Nicholson T, Goldstein D, Golovsky D, Ferguson R, et al. Bacillus Calmette-Guerin plus intravesical interferon alpha-2b in patients with superficial bladder cancer. Urology 1996;48:957–61, discussion 961–2.
   PubMed Web of Science ®Google Scholar
• Saxena S, Agarwal U, Agarwal A, Murthy NS, Mohanty NK. Adjuvant intravesical therapy based on in vitro cytotoxicity assay in management of superficial transitional cell cancer of urinary bladder. BJU Int 2006;98:1012–7.
   PubMedGoogle Scholar
• Cher DJ, Mosmann TR. Two types of murine helper T cell clone.II. Delayed-type hypersensitivity is mediated by TH1 clones. J Immunol 1987;138:3688–94.
   PubMed Web of Science ®Google Scholar
• Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7:145–73.
   PubMed Web of Science ®Google Scholar
• Stevens TL, Bossie A, Sanders VM, Fernandez-Botran R, Coffman RL, Mosmann TR, et al. Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature 1988;334:255–8.
   PubMed Web of Science ®Google Scholar
• Old LJ. Tumor necrosis factor, polypeptide mediator network. Nature 1987;326:330–1.
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Fitch FW. Anti-proliferative effect of IFN-gamma in immune regulation. I. IFN-gamma inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones. J Immunol 1988;140:4245–52.
   PubMed Web of Science ®Google Scholar
• Powrie FS, Menon RL, Coffman. Interleukin-4 and interleukin-10 synergize to inhibit cell-mediated immunity in vivo. Eur J Immunol 1993;23:3043–9.
   Google Scholar
• Goedegebuure PS, Lee KY, Matory YL, Peoples GE, Yoshino I, Eberlein TJ. Classification of CD4+ T helper cell clones in human melanoma. Cell Immunol 1994;156:170–9.
   PubMedGoogle Scholar
• Schoof DD, Terashima Y, Peoples GE, Goedegebuure PS, Andrews JV, Richie JP, et al. CD4+ T cell clones isolated from human renal cell carcinoma possess the functional characteristics of Th2 helper cells. Cell Immunol 1993;150:114–23.
   PubMedGoogle Scholar
• Bohle A, Nowc C, Ulmer AJ, Musehold J, Gerdes J, Hofstetter AG, et al. Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guerin immunotherapy. J Urol 1990;144:59–64.
   PubMed Web of Science ®Google Scholar
• De Reijke TM, de Boer EC, Kurth KH, Schamhart DH. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value. J Urol 1996;155:477–82.
   PubMed Web of Science ®Google Scholar
• Esuvaranathan K, Alexandroff AB, McIntyre M, Jackson AM, Prescott S, Chisholm GD, et al. Interleukin-6 production by bladder tumors is upregulated by BCG immunotherapy. J Urol 1995;154:572–5.
   PubMedGoogle Scholar
• Prescott S, James K, Hargreave TB, Chisholm GD, Smyth JF. Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy. J Urol 1990;144:1248–51.
   PubMed Web of Science ®Google Scholar
• Thalmann GN, Dewald B, Baggiolini M, and Studer UE. Interleukin-8 expression in the urine after BCG therapy: a potential predictor of tumor recurrence and progression. J Urol 1996;155:34A (abstr.)
   Google Scholar
• Barcellini W, Rizzardi GP, Borghi MO, Fain C, Lazzarin A, Meroni PL. TH1 and TH2 cytokine production by peripheral blood mononuclear cells from HIV-infected patients. AIDS 1994;8:757–62.
   PubMed Web of Science ®Google Scholar
• Peltz G. A role for CD4+ T-cell subsets producing a selective pattern of lymphokines in the pathogenesis of human chronic inflammatory and allergic diseases. Immunol Rev 1991;123:23–35.
   PubMedGoogle Scholar
• Modlin RL, Mehra V, Wong L, Fujimiya Y, Chang WC, Horwitz DA, et al. Suppressor T lymphocytes from lepromatous leprosy skin lesions. J Immunol 1986;137:2831–4.
   PubMedGoogle Scholar
• Elsasser-Beile U, Kolble N, Grussenmeyer T, Schultze-Seemann W, Wetterauer U, Gallati H, et al. Th1 and Th2 cytokine response patterns in leukocyte cultures of patients with urinary bladder, renal cell and prostate carcinomas. Tumor Bio l 1998;19:470–6.
   PubMedGoogle Scholar
• Agarwal A, Rani M, Saha G.K, Valarmathi TM, Bahadur S, Mohanty BK, et al. Disregulated expression of the Th2 cytokine gene in patients with intraoral squamous cell carcinoma. Immunol Invest 2003;32:17–30.
   PubMed Web of Science ®Google Scholar
• Agarwal A, Verma S, Burra U, Murthy NS, Mohanty NK, Saxena S. Flow cytometric analysis of Th1 and Th2 cytokines in PBMCs as a parameter of immunological dysfunction in patients of superficial transitional cell carcinoma of bladder. Cancer Immunol Immunother 2006;55:734–43.
   PubMed Web of Science ®Google Scholar
• Chen X, Woiciechowsky A, Raffegerst S, Schendel D, Kolb HJ, Roskrow M. Impaired expression of the CD3-zeta chain in peripheral blood T cells of patients with chronic myeloid leukaemia results in an increased susceptibility to apoptosis. Br J Haematol 2000;111:817–25.
   PubMed Web of Science ®Google Scholar
• Guarini A, Breccia M, Montefusco E, Petti MC, Zepparoni A, Vitale A, et al. Phenotypic and functional characterization of the host immune compartment of chronic myeloid leukaemia patients in complete haematological remission. Br J Haematol 2001;113:136–42.
   PubMed Web of Science ®Google Scholar
• Fortis C, Foppoli M, Gianotti L, Galli L, Citterio G, Consogno G, et al. Increased interleukin-10 serum levels in patients with solid tumours. Cancer Lett 1996;104:1–5.
   PubMed Web of Science ®Google Scholar
• Taniguchi K, Koga S, Nishikido M, Yamashita S, Sakuragi T, Kanetake H, et al. Systemic immune response after intravesical instillation of bacille Calmette-Guerin BCG for superficial bladder cancer. Clin Exp Immunol 1999;115:131–5.
   PubMedGoogle Scholar
• Pang AS, Morales A. BCG induced murine peritoneal exudate cells: cytotoxic activity against a syngeneic bladder tumor cell line. J Urol 1982;127:1225–9.
   PubMedGoogle Scholar
• Schmidt AC, Bouic PJ, Heyns CF, De Kock ML. Peripheral blood lymphocyte response in patients with superficial transitional cell carcinoma of the bladder treated with intravesical Bacillus Calmette-Guerin-—a useful marker of response?. Br J Urol 1993;71:179–82.
   PubMedGoogle Scholar
• Haaff EO, Catalona WJ, Ratliff TL. Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG J Urol 1986;136:970–4.
   Google Scholar
• Jackson AM, Alexandroff AB, Kelly RW, Skibinska A, Esuvaranathan K, Prescott S, et al. Changes in urinary cytokines and soluble intercellular adhesion molecule-1 ICAM-1, in bladder cancer patients after bacillus Calmette-Guerin BCG immunotherapy. Clin Exp Immunol 1995;99:369–75.
   PubMed Web of Science ®Google Scholar
• Jackson AM, Alexandrov AB, Prescott S, James K, Chisholm GD. Expression of adhesion molecules by bladder cancer cells: modulation by interferon-gamma and tumor necrosis factor-alpha. J Urol 1992;148:583–6.
   Google Scholar
• Trinchieri G, Perussia B. Immune interferon: a pleiotropic lymphokine with multiple effects. Immunol Today 1985;6:131–6.
   PubMedGoogle Scholar
• Kaempfer R, Gerez L, Farbstein H, Madar L, Hirschman O, Nussinovich R, et al. Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression. J Clin Oncol 1996;14:1778–86.
   PubMed Web of Science ®Google Scholar
• Hawkyard SJ, Jackson AM, Prescott S, James K, Chisholm GD. The effect of recombinant cytokines on bladder cancer cells in vitro. J Urol 1993;150:514–8.
   PubMedGoogle Scholar
• Roth MD. Interleukin 2 induces the expression of CD45RO and the memory phenotype by CD45RA+ peripheral blood lymphocytes. J Exp Med 1994;179:857–64.
   PubMedGoogle Scholar